Attention bias at baseline does not moderate the

effect of attention bias modification for depressive

symptoms

Hallvard Solbø Hagen¹, Jan Ivar Røssberg¹, Catherine J. Harmer^{2, 3}, Rune Jonassen⁴, Nils Inge Landrø²

Ragnhild Bø²

- ¹Institute of Clinical Medicine, University of Oslo, Norway
- ² Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Norway
- ³Department of Psychiatry, Oxford University, UK
- ⁴Faculty of Health Sciences, Oslo Metropolitan University, Norway
- Corresponding author at: h.s.hagen@medisin.uio.no (HSH)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

23	Background: Clinica	I trials of Attention	Bias Modification for	depressive sym	nptoms have consistently
----	---------------------	-----------------------	-----------------------	----------------	--------------------------

- 24 produced small effect sizes and mixed results. Therefore, identifying subpopulations for whom this
- 25 intervention works has been called for. Considering the intended mechanism behind Attention Bias
- 26 Modification, change of attentional bias, the level of bias at baseline may moderate its efficacy.
- 27 Methods: Participants with a history of depression (N=301) were randomized to receive two daily
- 28 sessions of either Attention Bias Modification or sham for 14 days. A response-based attention bias
- 29 score was calculated, and a moderator analysis was run at post-intervention and 1-month follow-up
- 30 measured by change in Hamilton Depression Rating Scale and Beck Depression Inventory II,
- 31 respectively.
- 32 Results: Baseline attention bias did not significantly moderate the effect of Attention Bias
- 33 Modification on any of the time points or depression measures.
- 34 **Conclusions:** Baseline attentional bias was not found useful for characterizing subgroups more likely
- 35 to benefit from ABM for depressive symptoms.
- 36

37 Introduction

38 Depression is a leading cause of disability worldwide (GBD 2019 Mental Disorders Collaborators

39 2022). Current treatment options are effective [2], but a considerable proportion of patients

40 experience residual symptoms and frequent relapses. Therefore, to improve treatment outcomes,

- 41 novel approaches are required. Attention Bias (AB), the selective attention to negatively valenced
- 42 information, is theorized to be a central mechanism of depression [3]. Meta-analyses show that
- 43 patients with both current (Peckham et al., 2010; Suslow et al., 2020) and remitted depression [6,7]
- 44 show AB for negative stimuli.

Attention Bias Modification (ABM) was developed to reduce negative AB. In a seminal study, it was
revealed that modification of AB decreased mood reactivity following a mood induction procedure
[8]. In the following decades, ABM has been found to decrease depressive symptoms (e.g. Hsu et al.,
2021; Jonassen et al., 2019) but effects have been small or non-significant in the early meta-analyses
[11–13]. Two more recent depression-specific meta-analyses showed small to moderate effect sizes
[14,15].

51 Under the requirements of precision medicine, a more fine-grained approach for personalizing 52 treatment has been advocated by the Lancet Commission of Depression [16]. Various potential 53 moderators have been put to the test to define participant characteristics that may predict the 54 treatment outcome of ABM. In anxiety research, several moderators have been identified (MacLeod 55 et al., 2019), but few moderators have been found when investigating depression. A higher baseline 56 score of anxiety [18] and baseline rumination [19] have been found to moderate the effect, though 57 non-significant moderator effects have also been reported [4]. A major problem in some of these 58 studies has been lack of statistical power.

59 Change in AB is the assumed causative agent of ABM and we therefore sought to analyze whether 60 the baseline level of AB would moderate the effect of ABM. A significant moderating effect of 61 baseline AB has been found in generalized social phobia [20], but has not, to our knowledge, been 62 tested appropriately in depressed patients. In a study on non-depressed college students, a 63 moderating effect was absent in a three-armed RCT (N=77), using a dot-probe task [21]. However, 64 pre-selecting individuals based on moderate levels of AB in eye-tracking in a group of depressed 65 individuals was found to have a lasting effect on depression [9], but moderation was not analyzed. This may indicate a more beneficial effect for individuals with more negative ABs. 66

The reliability of the traditional AB computation has repeatedly been found to be unacceptably low
[22–25]. This makes it both unapt for clinical use as it cannot be used at an individual level but also
reduces power [26]. We therefore applied a novel computational model that has been shown to

70 increase reliability to acceptable levels [27]. Rather than a total trial average of reaction times, this 71 response-based computation is more sensitive to fluctuations in attention. From our material, three 72 of the indexes can be calculated: vigilance, avoidance and the ratio between the absolute numbers. As the group mean AB has been found to be toward dysphoric images across different measurement 73 74 techniques [5,7], we chose vigilance as the metric of AB in this analysis. 75 Baseline AB could be used as an indicator of treatment strategy and this could help tailor treatment, 76 and consequently a more personalized treatment. We hypothesized that the baseline level of AB in a 77 sample of previously depressed participants would moderate the effect of ABM on depression 78 outcome with increasing effect for those displaying more extreme baseline AB scores.

79

80 Methods

81 **Participants**

82 The data analyzed in this paper is based on a previous double-blinded randomized controlled 83 trial including participants with residual depressive symptoms with preregistered moderator analyses. Participants were recruited after receiving treatment as outpatients and were 84 85 included in the study between May 6, 2014 to September 27, 2016 (ClinicalTrials.gov, 86 number NCT02658682; n=301) [10]. The study received approval from the Regional Ethical Committee for Medical and Health Research for Southern Norway (2014/217/REK Sør-Øst D) 87 88 and informed written consent was obtained prior to enrollment. Participants aged 18-65 89 were included if they, according to the Norwegian version of MINI International Neuropsychiatric Interview 6.0.0 (M.I.N.I.), met the criteria for recurrent remitted Major 90 91 Depressive Disorder (MDD), and having at least two prior episodes of depression. Exclusion 92 criteria were head trauma, current substance abuse, psychosis, bipolar disorder,

- 93 neurological disorders, and attention deficit disorders. The data was accessed in March
- 94 2024.

95 Randomization

- Participants were randomly allocated 1:1 to receive either active ABM or a sham condition and were
 provided with laptops to run the intervention at home. The laptops were pre-programmed by an
- 98 independent lab technician, thus ensuring blindness to study allocation for both participants and
- 99 outcome assessors. The study followed an ITT approach, implying that 37 participants who were
- 100 currently depressed and therefore wrongfully included were subjected to analysis.

101 Intervention

102 The ABM procedure was based on the dot probe procedure and was similar to the one described in 103 Browning et al. (2012). Participants were instructed to perform the task, consisting of 96 trials and 104 lasting for approx. 5-7 min, twice daily for 14 days. Each trial started with a fixation cross, followed by 105 a vertically positioned pair of images of faces and these were paired positive-negative, positive-106 neutral and negative-neutral. All pictures were from 4 databases: the Karolinska directed emotional 107 faces database (Lundqvist et al., 1998), Matsumoto and Ekman's Japanese and Caucasian Facial 108 Expressions of Emotion (Biehl et al., 1997) NimStim (Tottenham et al., 2009) and Ekman Pictures of 109 Facial Affect (Ekman & Friesen, 1976). The stimuli lasted 500ms or 1000ms (1:1) and was randomly 110 presented in either the first or last half of the session. The emotions expressed were fear, anger, 111 happiness, and neutrality. The pictures were immediately followed by a single or pair of dots (the 112 probe) which replaced the more positively valenced facial expression 87% of the time. The 113 participants were instructed to identify the number of dots as quickly and accurately as possible by 114 pressing one of two keys on the keyboard. The sham condition was identical except for a 50% chance 115 of the dot replacing either valence.

116 Assessments and outcomes

117	Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) and Beck Depression Inventory-II (BDI-II;
118	Beck et al., 1988) were used as outcomes and these were measured at baseline, immediately after
119	the two-week intervention, and 1 month post-intervention. These showed good internal consistency
120	with Cronbach's Alpha at 0.771, 0.813 and 0.814 (HDRS) and 0.918, 0.927 and 0.931 (BDI-II)
121	respectively. Reviewers underwent training using case examples. Throughout the trial, bi-weekly
122	supervision meetings were held to maintain consistent rating standards. Any deviations were
123	resolved through consensus among the reviewers. However, we did not formally assess the ICC
124	between interviewers.
125	Baseline AB was measured in a paradigm equal to a single round of the sham condition but with a
125	baseline Ab was measured in a paradigin equal to a single round of the shart condition but with a
126	new set of facial stimuli. Reaction times (RT) for responding to the probe by pressing one of two
127	designated keys on the keyboard were measured. The more negative expressions (e.g. neutral vs
128	positive) was defined as stimulus, thus defining valid trials as the ones were the dot-probe replaced
129	the more negative expression. In the invalid trials, the dot-probe replaced the least negative picture.
130	As there were no neutral-neutral trials, only the vigilance and avoidance scores were calculated. Each
131	individual reaction time of the valid scores was subtracted from the averaged score of the invalid
132	trials. Positive difference scores were averaged per participant and termed "vigilance" and negative
133	difference scores were averaged per participant and termed "avoidance". A vigilance-avoidance ratio
134	was also calculated. For comparison, traditional AB scores were also included where the mean RT of
135	the valid negative trials was subtracted from the mean RT of the invalid scores.

136 Statistical analysis

Statistical analyses were performed using R[31] in RStudio v2023.12.0[32]. There were missing data sets on HDRS 1-month (n=30 (10%)) and BDI-II 1-month (n=28 (9%)). These were excluded from the 1 month analyses. Missing data points (n=13) were replaced with a series mean as they were missing

140 completely at random. Descriptives, including correlation analyses, were conducted for baseline 141 measurements. A regression-based moderator analysis was performed using the PROCESS macro v4.3 [33] and assumptions were tested and met according to Hayes [34]. The predictor was set as 142 ABM, the moderator as baseline AB and outcome as BDI-II and HDRS at post-intervention or 1 month 143 144 post-intervention. The threshold for significance was set at 0.05. If significant, the interaction terms were probed at the 16th, 50th and 84th percentiles and regions of significance were examined using 145 146 the Johnson-Neyman technique. Bootstrapping was performed to obtain robust confidence intervals 147 for the interaction term (n=5000). All regression analyses were controlled for the respective 148 depression score at baseline. 149 The attention bias data was reduced by first removing trials outside 200-2000ms. Next, answers with 150 the wrong location were removed. Missing data was imputed using series mean. The reduction left 151 96.23% of the trials. No data points were considered multivariate outliers according to the criteria of 152 being positive on 2 out 3 on Mahalanobi's distance, Cook's distance and/or centered leverage, as 153 applied in [18]. After randomization, 37 individuals were found to fill the criteria for MDD (MDD+), 154 thus violating the inclusion criteria. Explorative analyses were run for the MDD+ group and selecting 155 for antidepressant status. 156 Reliability for the response-based score was measured using split-half analysis using even and odd 157 trial numbers to account for training effects [35]. All reliability correlation coefficients were 158 calculated using Spearman's rho and corrected with the Spearman-Brown prophecy formula. A 159 sensitivity power analysis was calculated using GPower [36].

160

161 **Results**

Baseline characteristics

Demographics are shown in Table 1. A correlation matrix between study variables is shown in Table
2. HDRS and BDI showed a significant correlation coefficient of 0.65, but response-based AB at

165	baseline showed a non-significant correlation of 0.05 with BDI-II and 0.02 with HDRS. Mean negative
166	vigilance was 88.7ms (31.1ms), mean negative avoidance -131ms (57.9ms) and the vigilance-
167	avoidance-ratio was 0.768 (0.418). Analyzing baseline AB by status of depression with independent
168	two-sided t-test showed a significantly higher value for vigilance in the Major Depressive Disorder
169	subgroup (MDD+) (MDD+: 100.0 ms vs MDD-: 87.1 ms, p=0.03) but non-significant differences in
170	mean avoidance (MDD+ -138.0 ms (54.9ms) vs MDD- 130.0 ms (58.3ms), p=0.422). Eighty
171	participants were using SSRIs or SNRIs (AD+), but there was no difference in mean vigilance (AD+:
172	91.9ms(28.9ms) vs AD-:87.5(31.9ms), p=0.30) or in mean avoidance in these groups (AD+: -
173	133ms(58.3ms) vs AD-:-130ms(57.4ms), p= 0.65). Traditional score AB at baseline across the sample

174 was not significantly different from zero (mean -1.07ms, Cl [-4.25 – 2.12], t(301)=-0.659, p=0.51).

175 Table 1. Demographics (means (SD) or frequencies).

	Placebo (n=148)	ABM (n=153)
Sex (females)	103	109
Age	41.5 (13.6)	40.2 (12.7)
Education level (ISCED) ^a	6.0 (1.2)	6.0 (1.1)
HDRS pre-intervention	8.3 (5.1)	9.3 (6,0)
HDRS post-intervention	8.7 (5.7)	8.4 (6,0)
HDRS post 1 month	8.1 (5.7)	8.6 (5.9)
BDI-II pre-intervention	13.5 (9.7)	15.1 (10.6)
BDI-II post-intervention	11.0 (9.7)	11.5 (10.5)
BDI-II post 1 month ^b	10.6 (9.5)	12.3 (10.1)
AB bl traditional ms	-1.2 (28.0)	-0.9 (28.0)
AB bl vigilance ms	87.0 (33.7)	90.1 (28.2)
AB bl avoidance ms	-130.0 (55.0)	-131.0 (60.3)
AB vigilance-avoidance ratio	0.7 (0.1)	0.7 (0.2)
Compliance ^c	80.0% (21.5)	83.4% (15.0)

Note. AB = Attentional Bias. ABM = Attention Bias Modification. BDI-II = Beck

Depression Inventory II. HDRS =Hamilton Depression Rating Scale. bl = baseline.

^a Missing data for 6 in the placebo group, 8 in the ABM group

 $^{\rm b}$ Missing data for 17 in the placebo group and 11 in the ABM group

^c percentage of max 2688 trials

176 **Table 2. Correlation matrix of psychometric scores.**

	Variable	1	2	3	4	5	6	7	8	9
1	BDI-II baseline									
2	BDI-II post	.81**								
3	BDI-II 1 month	.73**	.78**							
4	HDRS baseline	.65**	.56**	.48**						
5	HDRS post	.60**	.69**	.58**	.64**					

	medRxiv preprint doi: htt preprint (which was r		ed by peer	review) is t		under, who etuity.	has grante	d medRxiv a			
6	HDRS 1 month	.46**	.48**	.69**	.47**	.59**					
7	AB baseline traditional	02	.02	.04	06	.01	.04				
8	AB baseline avoidance	.02	.06	.06	.07	.00	.05	.34**			
9	AB baseline vigilance	.05	00	01	.02	01	01	28**	77**		
A/.	ata AD - Attantion Diag		Deel Dee	reccien In	untoru II		milton D	oprocion	Dating Coal	o Doorcon	corrolation

Note. AB = Attention Bias. BDI-II = Beck Depression Inventory II. HDRS = Hamilton Depression Rating Scale. Pearson correlation is used for all measures.

** Correlation is significant at the 0.01 level (2-tailed).

177

178	The dot-probe reaction times showed high split-half reliability (valid: r=0.96, invalid: r = 0.97) and the
179	correlation between mean average RT for valid and invalid trials were high (r=0.96). The split-half
180	reliability for average vigilance was 0.86 and 0.54 for avoidance, respectively. Subanalyses for
181	stimulus duration showed a reduction in reliability for both durations in vigilance (500ms: mean
182	r=0.70, 1000ms: mean r=0.74) and increase at 1000ms in avoidance (500ms: mean r: 0.48, 1000ms:
183	mean r: 0.58). Based on the reliability measurement, vigilance was used as measure of AB in the
184	moderator analyses.

185

186 Moderation analysis

- 187 There was a statistically significant improvement in HDRS at post-intervention in the intervention
- group compared to the sham group (F (1,309) = 6.78, η 2 = .02, p < .01], see Jonassen et al 2019 for
- 189 further details). Response-based baseline vigilance AB scores did not moderate the effect of ABM on
- 190 change in any of the outcomes.
- 191 For HDRS at post-intervention: F(4,295)=13.702, p<0.001, MSE=20.242. R²-change: 0.001,
- 192 F(1,295)=0.303, p=0.582, controlling for baseline HDRS. The slopes of the interaction effect are
- 193 represented in Fig 1. The bootstrapping confidence interval for HDRS post-intervention was
- 194 0.024 0.037, i.e., covering zero.
- 195 Baseline vigilance AB scores did not moderate the effect of ABM on reduction in BDI at post-
- 196 intervention: F(4,295)=0.949, p<0.0001, MSE:36.107. R²-change: 0.004, F(1,295)=1.1567, p=0.283.
- 197 Bootstrap CI: -0.014-0.0669. Excluding the (MDD+) did not affect the results.

- 198 Baseline vigilance AB scores did not moderate the effect of ABM on change in HDRS at 1 month
- 199 follow-up: F(4, 265)=22.719, p<0.001, MSE: 26.242. R²-change 0.000, F(1,265)=0.000, p=0.247.
- 200 Bootstrap CI: -0.070-0.016. Excluding the (MDD+) did not affect the results.
- 201 Baseline AB did not moderate the effect of ABM on change in BDI at 1 month follow-up:
- 202 F(4,267)=13.361, p<0.001, MSE:44.700. R²-change: 0.001, F(1,267)=0.021, p=0.885.
- 203 Bootstrap CI: -0.050-0.041. Excluding the (MDD+) did not affect the result. For full results, see
- 204 supplementary information.
- 205 Fig 1. Moderator analysis of baseline AB on depression outcomes
- 206

Note. A. Change in HDRS from baseline to post-intervention. B. Change in HDRS from baseline to 1
 month. C. Change in BDI-II from baseline to post-intervention. D. Change in BDI-II from baseline to 1
 month. Neither of the interaction effects were significant. ABM = Attention Bias Modification. BDI-II =
 Beck Depression Inventory II. HDRS =Hamilton Depression Rating Scale. RRS-B Rumination Response
 Scale – Brooding subscale

212

213 **Discussion**

- 214 The present study investigated response-based baseline AB as moderator for the effect of ABM on
- 215 depressive symptoms in a sample of participants with residual symptoms. No moderator effect was
- found in either depression outcome at post-intervention or after 1 month.

217 Given the assertion that the central mechanism of ABM is correction of AB, the lack of a moderating

effect of baseline AB is surprising [37]. Still, this is in line with the only other moderator study on

- 219 baseline AB, where a negative AB at baseline did not moderate the change in depression in a non-
- 220 clinical population [21]. These results might represent a false negative as the analysis of moderation
- probably was numerically underpowered (three arms, n=77) in addition to the use of the unreliable
- traditional AB score. On the other hand, pre-selecting for a group with a moderate negative baseline
- using a more reliable score, Hsu et al (2021) gave a significant effect of 0.72 points reduction per

week over four weeks on the HRSD. This could indicate an effect of pre-selecting on AB, but as nocontrol group was included, this remains uncertain.

Baseline AB as moderator for the effect of ABM has been more extensively studied in anxiety, though
results are mixed. Amir et al (2011) used a dot-probe task and found baseline AB towards threat to
moderate the response to the intervention in individuals with generalized social phobia. On the other
hand, in a study including children with social anxiety disorder, no moderating effect of baseline AB
was found on clinical outcome [38].

231 There are several explanations for the lack of moderation effect in our study. First, there was no

significant mean negative traditional AB at baseline. This is surprising, considering the results of a

233 meta-analysis where previously depressed individuals were found to have a negative traditional AB,

comparable to the AB found among currently depressed individuals [7]. Still, in never-depressed

people a neutral average AB is not the norm, but rather a positive bias [39]. As such, the level in our

sample represents a negative deviation from never-depressed.

237 Second, though the response-based AB calculation showed high reliability, it was not correlated with 238 any of the baseline depression scores, thus possibly being of questionable validity as a measurement 239 of depression. This corroborates previous findings on depression scores and AB measurement 240 [40,41]. The group differences in AB between depressed and non-depressed has been a consistent 241 finding and thus leaves the question of what the relationship between AB and depression represents. 242 The use of sum-scores as outcome may be conceal the effect as depression represents a highly 243 heterogenous diagnosis but no subscale to link depression to attention bias has been identified or 244 agreed [40,42].

Third, some choices in the baseline AB measurement paradigm may have affected the result. In Kaiser et al (2018), the combination of emotionally congruent information in combination with selfreferential cues were the most potent at eliciting negative AB. The importance of relevance to the participant was found for positive biases in Pool et al (2016). The dot-probe task may be less apt at

249 assessing AB due to the lack of self-referential material in our study. Stimulus lengths have also been 250 found to affect the AB detection. In our study, a stimulus length of 500 ms and 1000 ms was set at a 251 ratio of 1:1. Donaldson et al (2007) found a significant negative baseline AB in depressed individuals 252 when extending stimulus presentations to 1000 ms, which was not found at 500 ms. Further, eye-253 tracking-studies have supported the notion of a bias in the latter stages of attention in depression 254 [5]. If AB is dynamic, rather than static, mean reaction times derived from longer stimulus durations 255 may provide a more reliable measurement, such as those found in eye-tracking studies (Skinner et 256 al., 2018).

257 Fourth, the low depression levels in the current sample may be of relevance to the null finding. With 258 a baseline BDI-II score of 14.3 in the sample, smaller improvements would be expected than in a 259 clinically depressed sample. Still, a baseline AB has been found in samples with lower baseline BDI 260 scores. In Arenliu et al (2023), the baseline score of BDI-II in a non-clinical population was 11.4, lower 261 than our baseline, and still a clear AB was found, though by using eye tracking instead of dot-probe. 262 In another sample, Joorman and Gotlib (2007) found a baseline AB in both depressed and formerly 263 depressed patients, the latter with a mean BDI of 5.21, using a dot-probe stimulation period of 264 1000ms. It is therefore unclear whether the low level of depression may have affected the result, but 265 limited opportunity for change in the outcome will anyhow limit the variance to explain. 266 Fifth, 27% (n=80) of the current sample used antidepressant medication, which could partly explain 267 the small negative traditional AB. SSRIs have been found to reduce attentional vigilance to threat in 268 healthy volunteers [46] but has to our knowledge not been studied in a clinically depressed 269 population Likewise, differences in AB using eye-tracking also revealed differences between 270 medicated and non-medicated individuals with MDD [47]. Still, considering the non-significant 271 difference in baseline response-based AB between antidepressant-users and non-users, the effect 272 does not seem to be the explain the lack of negative AB.

273 It is difficult to know if previous psychotherapy affected the baseline measurement here. The

research is scarce but a significant reduction after both CBT and positive psychology interventions in
AB using eye-tracking technology has been found [48]. Being a different detection method, it is not
possible to translate these findings to our study as the detection methods have been found to be
largely uncorrelated [25]. Furthermore, information of the types of pre-intervention psychotherapy
was not collected.

279 Sixth, the lack of moderation effect may be attributed to the limited effect of the intervention and 280 the similarity of the sham comparator. The total change in HDRS for the intervention group was small 281 (-0.9 points vs +0.5 for the sham condition) and not significant for BDI-II, possibly due to the low 282 baseline depression levels. The use of a sham condition as control to address the clinical utility of 283 ABM has been questioned because it is not a clinically relevant alternative [49] and also due to the 284 effect on attentional processes by both conditions [22,50]. It may also alter moderating factors of AB 285 such as attentional control (Basanovic and MacLeod, 2017) and improvement in attentional control, 286 following ABM, has been found to correlate with clinical improvement [22,50]. It may therefore mask 287 the effect by itself affecting AB, reducing the chance of finding a statistically significant result. Still, 288 Hsu et al (2021), pre-selecting for moderate AB, found a significant difference in depression scores 289 between sham and active ABM, but no difference between sham and assessment-only. 290 Seventh, in this study there was a significantly larger change in HDRS in the ABM group than the 291 control group, but the change in the traditional AB was small and not significantly, as previously 292 reported [10]. Macleod and Grafton (2016) showed how a lack of significant change in AB often 293 resulted in lack of change in depression outcomes. The eliciting of a significant change in AB is 294 necessary to determine if the procedure was effective, rather than making claims about the effect of 295 the process [52]. This may have affected the size of the reduction and may be a consequence of the 296 mentioned similarity in conditions.

297

298 Strengths and limitations

299	This RCT represents the largest RCT in individuals with residual depression, using a well-known
300	procedure with stringent conditions. In addressing the residual nature of depression, it answers an
301	important question of whether using baseline AB moderates the effect of ABM. By applying the
302	response-based AB measure, a high reliability secures the frequently overlooked problem of poor
303	reliability on power calculations [26], and the consequent underestimation of the number of
304	participants needed. As this is secondary analysis no a priori power calculation was performed, but a
305	sensitivity power analysis [53] using GPower 3.1.9.7 fixing α = 0.05 and power at 0.90 with n=301
306	returns a possible detection of effect sizes of f^2 = 0.04 indicating an unlikely false negative result [36].
307	Generalization to other populations is limited due to lack of generalizability due to low baseline
308	depression scores. Another issue lies in the lack of sad facial expressions in the stimuli as this has
309	shown to be the most potent stimuli in eliciting AB in depression. Furthermore, the analysis of single
310	moderators is possibly not sufficient to define the treatment of MDD [54] and multivariate
311	approaches may be more clinically useful, such as the Personalized Advantage Index that has shown
312	promising results in psychotherapy research [55].

313 Future directions

As previously suggested, the validity of the response-based index should be studied and outcome measures evaluated further in clinically depressed populations [40]. Further, we support the notion that both cleaning of data and reliability measure should be registered before inclusion as suggested by Molloy & Anderson (2020). Furthermore, the use of a sham condition as control group in clinical trials should be carefully considered due to its similarity to the active intervention.

319 Conclusion

A response-based baseline measure of attention bias did not moderate the effect of ABM despite a
 reliable AB measure, thus rendering it unsuited to define individuals with increased effect of ABM.

- 322 Furthermore, it was not correlated with levels of depression and further research to clarify this
- 323 relationship and the psychometric validity is needed.

324

325 Acknowledgements

- 326 Acknowledgements: We want to thank Luigi Maglanoc, Eva Hilland, Inger Marie Andreassen, Adrian
- 327 Dahl Askelund, Dani Beck, Sandra Aakjær Bruun, Jenny Tveit Kojan, Nils Eivind Holth Landrø, Elise
- 328 Solbu Kleven and Julie Wasmuth for their contribution to the data collection. Further, we thank Kari
- 329 Agnes Myhre, Erlend Bøen, MD, PhD and Torkil Berge at Diakonhjemmet Hospital, Division of
- 330 Psychiatry, for help and support during the recruiting period. We also thank our external recruitment
- 331 sites, Unicare, Tore C. Stiles at Coperiosenteret AS, Torgny Syrstad, MD, Synergi Helse AS and
- 332 Lovisenberg Hospital.
- 333
- 334
- 335

336 **References**

- Global, regional, and national burden of 12 mental disorders in 204 countries and territories,
 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet
 Psychiatry. 2022 Feb 1;9(2):137–50. doi:10.1016/S2215-0366(21)00395-3.
- Cuijpers P, Quero S, Dowrick C, Arroll B. Psychological Treatment of Depression in Primary Care:
 Recent Developments. Curr Psychiatry Rep. 2019 Nov 23;21(12):129. doi:10.1007/s11920-019 1117-x.
- Beck AT. The Evolution of the Cognitive Model of Depression and Its Neurobiological Correlates.
 AJP. 2008 Aug;165(8):969–77. doi:10.1176/appi.ajp.2008.08050721.
- Peckham AD, McHugh RK, Otto MW. A meta-analysis of the magnitude of biased attention in depression. Depression and Anxiety. 2010;27(12):1135–42. doi:10.1002/da.20755.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.10.24317072; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 347 5. Suslow T, Hußlack A, Kersting A, Bodenschatz CM. Attentional biases to emotional information in 348 clinical depression: A systematic and meta-analytic review of eye tracking findings. J Affect 349 Disord. 2020 Sep 1;274:632-42. doi:10.1016/j.jad.2020.05.140.
- 350 Joormann J, Gotlib IH. Selective attention to emotional faces following recovery from depression. 6. 351 Journal of Abnormal Psychology. 2007 Feb;116(1):80–5. doi:10.1037/0021-843X.116.1.80.
- 352 7. Shamai-Leshem D, Linetzky M, Bar-Haim Y. Attention Biases in Previously Depressed Individuals: 353 A Meta-Analysis and Implications for Depression Recurrence. Cogn Ther Res. 2022 Dec 354 1;46(6):1033-48. doi:10.1007/s10608-022-10331-y.
- MacLeod C, Rutherford E, Campbell L, Ebsworthy G, Holker L. Selective attention and emotional 355 8. 356 vulnerability: Assessing the causal basis of their association through the experimental 357 manipulation of attentional bias. Journal of Abnormal Psychology. 2002 Feb;111(1):107–23. doi:10.1037/0021-843X.111.1.107. 358
- 359 Hsu KJ, Shumake J, Caffey K, Risom S, Labrada J, Smits JAJ, et al. Efficacy of attention bias 9. 360 modification training for depressed adults: a randomized clinical trial. Psychological Medicine. 2021 Mar 26;1-9. doi:10.1017/S0033291721000702. 361

10. Jonassen R, Harmer CJ, Hilland E, Maglanoc LA, Kraft B, Browning M, et al. Effects of Attentional 362 Bias Modification on residual symptoms in depression: a randomized controlled trial. BMC 363 Psychiatry. 2019 May 8;19(1):141. doi:10.1186/s12888-019-2105-8. 364

365 11. Cristea IA, Kok RN, Cuijpers P. Efficacy of cognitive bias modification interventions in anxiety and 366 depression: meta-analysis. Br J Psychiatry. 2015 Jan;206(1):7–16. 367 doi:10.1192/bjp.bp.114.146761.

368 12. Fodor LA, Georgescu R, Cuijpers P, Szamoskozi Ş, David D, Furukawa TA, et al. Efficacy of 369 cognitive bias modification interventions in anxiety and depressive disorders: a systematic 370 review and network meta-analysis. The Lancet Psychiatry. 2020 Jun 1;7(6):506–14. 371 doi:10.1016/S2215-0366(20)30130-9.

- 372 13. Hallion LS, Ruscio AM. A meta-analysis of the effect of cognitive bias modification on anxiety and 373 depression. Psychological Bulletin. 2011 Nov;137(6):940–58. doi:10.1037/a0024355.
- 374 14. Li J, Ma H, Yang H, Yu H, Zhang N. Cognitive bias modification for adult's depression: A systematic 375 review and meta-analysis. Front Psychol. 2023 Jan 19;13:968638. 376 doi:10.3389/fpsyg.2022.968638.
- 377 15. Xia H sha, Li Y xi, Zhang Q yun, Zhong D ling, Liu X bo, Gou X yun, et al. Attention bias 378 modification for depression: A systematic review and meta-analysis. Front Psychiatry. 2023 Mar 379 10;14:1098610. doi:10.3389/fpsyt.2023.1098610.
- 16. Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, et al. Time for united action on 380 depression: a Lancet–World Psychiatric Association Commission. The Lancet. 2022 Mar 381 5;399(10328):957-1022. doi:10.1016/S0140-6736(21)02141-3. 382
- 383 17. MacLeod C, Grafton B, Notebaert L. Anxiety-Linked Attentional Bias: Is It Reliable? Annu Rev Clin 384 Psychol. 2019 May 7;15(1):529-54. doi:10.1146/annurev-clinpsy-050718-095505.

- 385 18. Bø R, Kraft B, Jonassen R, Harmer CJ, Hilland E, Stiles TC, et al. Symptom severity moderates the 386 outcome of attention bias modification for depression: An exploratory study. Journal of 387 Psychiatric Research. 2021 Jun;138:528–34. doi:10.1016/j.jpsychires.2021.04.027.
- 388 19. Arditte KA, Joormann J. Rumination Moderates the Effects of Cognitive Bias Modification of 389 Attention. Cogn Ther Res. 2014 Apr;38(2):189–99. doi:10.1007/s10608-013-9581-9.
- 390 20. Amir N, Taylor CT, Donohue MC. Predictors of Response to an Attention Modification Program in 391 Generalized Social Phobia. J Consult Clin Psychol. 2011 Aug;79(4):533-41. 392 doi:10.1037/a0023808.
- 21. Yang W, Ding Z, Dai T, Peng F, Zhang JX. Attention Bias Modification training in individuals with 393 394 depressive symptoms: A randomized controlled trial. Journal of Behavior Therapy and 395 Experimental Psychiatry. 2015 Dec 1;49:101–11. doi:10.1016/j.jbtep.2014.08.005.
- 396 22. McNally RJ, Enock PM, Tsai C, Tousian M. Attention bias modification for reducing speech anxiety. Behav Res Ther. 2013 Dec;51(12):882-8. doi:10.1016/j.brat.2013.10.001. 397
- 398 23. Meissel EEE, Liu H, Stevens ES, Evans TC, Britton JC, Letkiewicz AM, et al. The Reliability and 399 Validity of Response-Based Measures of Attention Bias. Cogn Ther Res. 2022 Feb 1;46(1):146-60. 400 doi:10.1007/s10608-021-10212-w.
- 401 24. Rodebaugh TL, Scullin RB, Langer JK, Dixon DJ, Huppert JD, Bernstein A, et al. Unreliability as a 402 Threat to Understanding Psychopathology: The Cautionary Tale of Attentional Bias. J Abnorm Psychol. 2016 Aug;125(6):840-51. doi:10.1037/abn0000184. 403
- 404 25. Waechter S, Nelson AL, Wright C, Hyatt A, Oakman J. Measuring Attentional Bias to Threat: 405 Reliability of Dot Probe and Eye Movement Indices. Cogn Ther Res. 2014 Jun 1;38(3):313–33. 406 doi:10.1007/s10608-013-9588-2.
- 407 26. Parsons S, Kruijt AW, Fox E. Psychological Science Needs a Standard Practice of Reporting the 408 Reliability of Cognitive-Behavioral Measurements. Advances in Methods and Practices in 409 Psychological Science. 2019 Dec 1;2(4):378–95. doi:10.1177/2515245919879695.
- 410 27. Evans TC, Britton JC. Improving the psychometric properties of dot-probe attention measures 411 using response-based computation. Journal of Behavior Therapy and Experimental Psychiatry. 412 2018 Sep 1;60:95–103. doi:10.1016/j.jbtep.2018.01.009.
- 413 28. Browning M, Holmes EA, Charles M, Cowen PJ, Harmer CJ. Using Attentional Bias Modification as 414 a Cognitive Vaccine Against Depression. Biological Psychiatry. 2012 Oct 1;72(7):572–9. 415 doi:10.1016/j.biopsych.2012.04.014.
- 416 29. Hamilton M. A RATING SCALE FOR DEPRESSION. Journal of Neurology, Neurosurgery & 417 Psychiatry. 1960 Feb 1;23(1):56–62. doi:10.1136/jnnp.23.1.56.
- 30. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: 418 419 Twenty-five years of evaluation. Clinical Psychology Review. 1988 Jan 1;8(1):77–100. 420 doi:10.1016/0272-7358(88)90050-5.
- 421 31. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R 422 Foundation for Statistical Computing; 2024.
- 423 32. RStudio Team. Rstudio [Internet]. RStudio, PBC; 2024. Available from: https://www.rstudio.com/

- 424 33. Hayes A. PROCESS [Internet]. 2022. Available from: www.processmacro.org
- 425 34. Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression426 based approach. Second edition. New York, London: The Guilford Press; 2018. (Methodology in
 427 the social sciences).
- 428 35. Pronk T, Molenaar D, Wiers RW, Murre J. Methods to split cognitive task data for estimating
 429 split-half reliability: A comprehensive review and systematic assessment. Psychon Bull Rev. 2022
 430 Feb 1;29(1):44–54. doi:10.3758/s13423-021-01948-3.
- 431 36. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for
 432 correlation and regression analyses. Behavior Research Methods. 2009 Nov;41(4):1149–60.
 433 doi:10.3758/BRM.41.4.1149.
- 434 37. Grafton B, MacLeod C, Rudaizky D, Holmes EA, Salemink E, Fox E, et al. Confusing procedures
 435 with process when appraising the impact of cognitive bias modification on emotional
 436 vulnerability. The British Journal of Psychiatry. 2017 Nov;211(5):266–71.
 437 doi:10.1192/bjp.bp.115.176123.
- 438 38. Pergamin-Hight L, Pine DS, Fox NA, Bar-Haim Y. Attention bias modification for youth with social
 439 anxiety disorder. Journal of Child Psychology and Psychiatry. 2016;57(11):1317–25.
 440 doi:10.1111/jcpp.12599.
- 39. Pool E, Brosch T, Delplanque S, Sander D. Attentional bias for positive emotional stimuli: A metaanalytic investigation. Psychological Bulletin. 2016;142(1):79–106. doi:10.1037/bul0000026.
- 40. Beevers CG, Mullarkey MC, Dainer-Best J, Stewart RA, Labrada J, Allen JJB, et al. Association
 Between Negative Cognitive Bias and Depression: A Symptom-Level Approach. 2019;
- 445 41. Marchetti I, Everaert J, Dainer-Best J, Loeys T, Beevers CG, Koster EHW. Specificity and overlap of
 446 attention and memory biases in depression. Journal of Affective Disorders. 2018 Jan 1;225:404–
 447 12. doi:10.1016/j.jad.2017.08.037.
- 42. Fried E. Moving forward: how depression heterogeneity hinders progress in treatment and
 research. Expert Review of Neurotherapeutics. 2017 May 4;17(5):423–5.
 doi:10.1080/14737175.2017.1307737.
- 43. Kaiser RH, Snyder HR, Goer F, Clegg R, Ironside M, Pizzagalli DA. Attention Bias in Rumination and
 Depression: Cognitive Mechanisms and Brain Networks. Clin Psychol Sci. 2018 Nov;6(6):765–82.
 doi:10.1177/2167702618797935.
- 44. Skinner IW, Hübscher M, Moseley GL, Lee H, Wand BM, Traeger AC, et al. The reliability of
 eyetracking to assess attentional bias to threatening words in healthy individuals. Behav Res.
 2018 Oct 1;50(5):1778–92. doi:10.3758/s13428-017-0946-y.
- 45. Arenliu A, Konjufca J, Meiran N, Weine S, Langenecker SA. Attentional Bias Among High and Low
 Ruminators: Eye Tracking Study in a Non-Clinical Population. SAGE Open. 2023 Apr
 1;13(2):21582440231170804. doi:10.1177/21582440231170804.
- 46. Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ. Short-term serotonergic but not
 461 noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy
 462 volunteers. International Journal of Neuropsychopharmacology. 2009 Mar 1;12(2):169–79.
 463 doi:10.1017/S1461145708009164.

- 464 47. Wells TT, Clerkin EM, Ellis AJ, Beevers CG. Effect of Antidepressant Medication Use on Emotional 465 Information Processing in Major Depression. Am J Psychiatry. 2014 Feb 1;171(2):195–200. 466 doi:10.1176/appi.ajp.2013.12091243.
- 467 48. Vazquez C, Duque A, Blanco I, Pascual T, Poyato N, Lopez-Gomez I, et al. CBT and positive 468 psychology interventions for clinical depression promote healthy attentional biases: An eye-469 tracking study. Depression and Anxiety. 2018;35(10):966–73. doi:10.1002/da.22786.
- 470 49. Blackwell SE, Woud ML, MacLeod C. A Question of Control? Examining the Role of Control 471 Conditions in Experimental Psychopathology using the Example of Cognitive Bias Modification 472 Research. The Spanish Journal of Psychology. 2017 Jan;20(e54):1–13. doi:10.1017/sjp.2017.41.
- 473 50. Heeren A, Mogoase C, McNally RJ, Schmitz A, Philippot P. Does attention bias modification 474 improve attentional control? A double-blind randomized experiment with individuals with social anxiety disorder. Journal of Anxiety Disorders. 2015 Jan 1;29:35-42. 475 476 doi:10.1016/j.janxdis.2014.10.007.
- 477 51. Basanovic J, MacLeod C. Does anxiety-linked attentional bias to threatening information reflect 478 bias in the setting of attentional goals, or bias in the execution of attentional goals? Cognition 479 and Emotion. 2017 Apr 3;31(3):538-51. doi:10.1080/02699931.2016.1138931.
- 480 52. MacLeod C, Grafton B. Anxiety-linked attentional bias and its modification: Illustrating the importance of distinguishing processes and procedures in experimental psychopathology 481 482 research. Behaviour Research and Therapy. 2016 Nov 1;86:68-86. 483 doi:10.1016/j.brat.2016.07.005.
- 484 53. Lakens D. Sample Size Justification. Collabra: Psychology. 2022 Mar 22;8(1):33267. 485 doi:10.1525/collabra.33267.
- 486 54. Cohen ZD, DeRubeis RJ. Treatment Selection in Depression. Annu Rev Clin Psychol. 2018 May 7;14(1):209-36. doi:10.1146/annurev-clinpsy-050817-084746. 487

488 55. van Bronswijk SC, DeRubeis RJ, Lemmens LHJM, Peeters FPML, Keefe JR, Cohen ZD, et al. 489 Precision medicine for long-term depression outcomes using the Personalized Advantage Index 490 approach: cognitive therapy or interpersonal psychotherapy? Psychol Med. 2021;51(2):279-89. 491 doi:10.1017/S0033291719003192.

492 56. Molloy A, Anderson PL. Evaluating the reliability of attention bias and attention bias variability 493 measures in the dot-probe task among people with social anxiety disorder. Psychological 494 Assessment. 2020;32(9):883-8. doi:10.1037/pas0000912.




Fig1.tif